Ramatroban

Ramatroban

Gene therapy
Clinical data
Routes of administration	Oral
Physiological data
Legal status
Legal status	In general: ℞ (Prescription only)
Pharmacokinetic data
Identifiers
IUPAC name 3-[(3R)-3-[(4-fluorophenyl)sulfonylamino]-1,2,3,4-tetrahydrocarbazol-9-yl]propanoic acid
CAS Number	116649-85-5
PubChem Template:Abbreviation	123879
Chemical and physical data
Formula	C21H21FN2O4S
Molar mass	416.46 g/mol
3D model (JSmol)	Interactive image
SMILES C1CC2=C(CC1NS(=O)(=O)C3=CC=C(C=C3)F)C4=CC=CC=C4N2CCC(=O)O

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Ramatroban (INN) is a thromboxane receptor antagonist indicated for the treatment of coronary artery disease. It has also been used for the treatment of asthma.

It was developed by the German pharmaceutical company Bayer AG and is co-marketed in Japan by Bayer and Nippon Shinyaku Co. Ltd. under the tradename Baynas.

References

• Template:Ja icon Baynas